Baader Bank Aktiengesellschaft Buys Shares of 777 IDEXX Laboratories, Inc. $IDXX

Key Points

• Baader Bank Aktiengesellschaft acquired 777 shares of IDEXX Laboratories, Inc. for approximately $415,000 in the second quarter.
• IDEXX's latest earnings report showed a profit of $3.63 per share, exceeding analysts' expectations, alongside a 10.6% year-over-year revenue increase.
• Current institutional ownership stands at 87.84% of IDEXX's stock, indicating significant investment interest among major investors.

Baader Bank Aktiengesellschaft acquired a new stake in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report) in the 2nd quarter, according to the company in its most recent filing with the SEC. The institutional investor acquired 777 shares of the company's stock, valued at approximately $415,000.

Several other hedge funds and other institutional investors have also recently made changes to their positions in IDXX. Sivia Capital Partners LLC purchased a new position in IDEXX Laboratories in the 2nd quarter worth $265,000. Pallas Capital Advisors LLC raised its stake in IDEXX Laboratories by 109.7% in the 2nd quarter. Pallas Capital Advisors LLC now owns 2,334 shares of the company's stock worth $1,252,000 after acquiring an additional 1,221 shares during the last quarter. Financiere des Professionnels Fonds d investissement inc. purchased a new position in IDEXX Laboratories in the 2nd quarter worth $147,000. Westmount Partners LLC purchased a new position in IDEXX Laboratories in the 2nd quarter worth $215,000. Finally, Czech National Bank raised its stake in IDEXX Laboratories by 4.5% in the 2nd quarter. Czech National Bank now owns 19,657 shares of the company's stock worth $10,543,000 after acquiring an additional 850 shares during the last quarter. Hedge funds and other institutional investors own 87.84% of the company's stock.

Insider Buying and Selling at IDEXX Laboratories

In related news, EVP Nimrata Hunt sold 7,143 shares of the company's stock in a transaction that occurred on Wednesday, August 6th. The stock was sold at an average price of $630.43, for a total value of $4,503,161.49. Following the transaction, the executive vice president directly owned 18,007 shares in the company, valued at approximately $11,352,153.01. This represents a 28.40% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, EVP Sharon E. Underberg sold 5,450 shares of the company's stock in a transaction that occurred on Friday, August 8th. The shares were sold at an average price of $651.60, for a total value of $3,551,220.00. Following the completion of the transaction, the executive vice president owned 6,156 shares in the company, valued at $4,011,249.60. This represents a 46.96% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders sold 54,057 shares of company stock worth $34,293,468. 0.98% of the stock is owned by company insiders.

Analysts Set New Price Targets

A number of brokerages recently issued reports on IDXX. Stifel Nicolaus set a $640.00 target price on IDEXX Laboratories in a research note on Monday, August 4th. BTIG Research raised their target price on IDEXX Laboratories from $545.00 to $785.00 and gave the stock a "buy" rating in a research note on Tuesday, August 5th. Jefferies Financial Group assumed coverage on IDEXX Laboratories in a research note on Tuesday, July 1st. They set a "buy" rating and a $625.00 price objective for the company. Wall Street Zen upgraded IDEXX Laboratories from a "buy" rating to a "strong-buy" rating in a research note on Saturday. Finally, Leerink Partners lifted their price objective on IDEXX Laboratories from $580.00 to $600.00 and gave the company an "outperform" rating in a research note on Thursday, July 17th. One investment analyst has rated the stock with a Strong Buy rating, six have given a Buy rating and three have assigned a Hold rating to the company's stock. Based on data from MarketBeat, IDEXX Laboratories currently has an average rating of "Moderate Buy" and a consensus price target of $649.44.

IDEXX Laboratories Price Performance

Shares of IDEXX Laboratories stock traded up $0.65 on Friday, hitting $656.16. 981,520 shares of the company were exchanged, compared to its average volume of 374,016. The stock has a market capitalization of $52.50 billion, a price-to-earnings ratio of 54.63, a price-to-earnings-growth ratio of 4.25 and a beta of 1.56. The company has a 50-day moving average price of $614.44 and a 200 day moving average price of $520.96. IDEXX Laboratories, Inc. has a 1-year low of $356.14 and a 1-year high of $688.12. The company has a quick ratio of 0.79, a current ratio of 1.11 and a debt-to-equity ratio of 0.31.

IDEXX Laboratories (NASDAQ:IDXX - Get Free Report) last issued its earnings results on Monday, August 4th. The company reported $3.63 earnings per share for the quarter, topping the consensus estimate of $3.28 by $0.35. The business had revenue of $1.11 billion for the quarter, compared to analysts' expectations of $1.06 billion. IDEXX Laboratories had a return on equity of 64.42% and a net margin of 24.41%.The business's revenue for the quarter was up 10.6% compared to the same quarter last year. During the same period in the previous year, the firm posted $2.44 EPS. IDEXX Laboratories has set its FY 2025 guidance at 12.400-12.760 EPS. As a group, sell-side analysts predict that IDEXX Laboratories, Inc. will post 11.93 earnings per share for the current fiscal year.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.